The targeted therapy neladalkib has been granted accelerated approval by the Food and Drug Administration (FDA) to treat advanced non-small cell lung cancer driven by the ALK mutation.
Research to develop the drug (brand name Nelkarmi), as well as the clinical trial that resulted in the FDA approval, were led at Memorial Sloan Kettering Cancer Center (MSK) by thoracic medical oncologist and early drug development specialist Alexander Drilon, MD. Neladalkib is made by Nuvalent.
“Patients with advanced ALK-positive lung cancer now have another treatment option when other ALK inhibitors, including lorlatinib, have stopped working,” says Dr. Drilon. “Neladalkib was designed to minimize neurological side effects seen with prior drugs and to shrink cancer, including cancer that has spread to the brain.”
To take neladalkib, patients must have already received either:
- one prior ALK tyrosine kinase inhibitor (TKI) consisting of alectinib, or
- Two or more ALK TKIs and platinum-based chemotherapy.
How neladalkib overcomes lung cancer driven by ALK
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, and ALK fusions occur in up to 5% of NSCLC patients. This ALK genetic alteration acts like a jammed switch that’s stuck in the “on” position, signaling cells to grow out of control, driving cancer.
There are already six approved TKIs to treat ALK-driven lung cancer. But lung cancer cells can become resistant to them over time. Some of these therapies can also affect the brain, causing side effects such as dizziness, imbalance, and changes to mood and thinking.
Neladalkib was designed to more precisely target ALK than previous therapies to reduce the side effects caused by accidental injury to healthy cells. The drug was also created to act against ALK mutations that have proved resistant to other treatments. Neladalkib can penetrate the blood-brain barrier, meaning it can be effective against cancer cells that have spread (metastasized) to the brain.
“Lung cancers with ALK mutations can be particularly challenging to control, especially when two or more mutations occur,” Dr. Drilon says. “Thankfully, neladalkib can work well despite these mutations.”
Side effects of neladalkib
Neladalkib was designed to reduce side effects that proved challenging with earlier treatments. However, it does have side effects that doctors and patients must consider.
The most serious can include kidney problems, eye toxicity, and risks to unborn babies.
The most common include liver problems, muscle and bone pain, constipation, altered taste, nerve pain, swelling, and fatigue.
See highlights from the FDA’s prescribing information
ALKOVE-1 clinical trial that led to FDA accelerated approval
The FDA approval of neladalkib is based on the ALKOVE-1 clinical trial, involving more than 220 patients at over 70 hospitals. Neladalkib is a pill taken once daily.
-
Among patients who had only taken alectinib before they began the trial:
- 49% responded to neladalkib.
- Of those, 76% kept responding for at least six months.
- 52% kept responding for at least 12 months.
-
Among patients who received two or more prior ALK TKIs, including lorlatinib, and platinum-based chemotherapy:
- 32% responded to neladalkib.
- Of those, 69% held their response for at least six months.
- 51% responded for at least 12 months.
Next steps for neladalkib
Accelerated approval from the FDA means further studies are required to confirm the expected benefits of neladalkib. The FDA developed the accelerated approval program to allow for earlier approval of drugs that treat serious conditions and fill an unmet medical need.
The drug is also being explored in another clinical trial in which patients may receive neladalkib or a comparator drug as their first targeted therapy for advanced ALK positive lung cancer.
Key Takeaways
- The FDA gave accelerated approval to neladalkib, a new targeted drug for advanced non-small cell lung cancer with an ALK genetic change. It is for patients whose cancer has already been treated with certain other ALK drugs, or with multiple ALK drugs and chemotherapy.
- ALK changes can act like a switch stuck in the “on” position, causing cancer cells to grow too quickly. Although other ALK-targeting drugs exist, cancers can become resistant to them over time.
- Neladalkib was designed to target resistant ALK cancer cells more precisely and may cause fewer effects by limiting damage to healthy cells. It can also cross the blood-brain barrier, which may help treat cancer that has spread to the brain.
- In a clinical trial of more than 220 patients, 49% previously treated only with alectinib responded to the drug, while 32% of more heavily treated patients responded. Because the approval is accelerated, more studies are still needed to confirm the drug’s long-term benefits and safety.
Dr. Drilon’s research is supported by the MSK donor community, including Nonna’s Garden Foundation, The Gibbons Scattone Family Foundation, Stage4Hope, Keren Phillips and Deborah Kazis-Taylor for the Earle and Judy Kazis Foundation Fund, Sam K. Simon, Stephen J. Squeri, LesLois Shaw Foundation, and Break Through Cancer.
Dr. Drilon holds the Carol Bassok Lowenstein Chair.
Disclosures
The ALKOVE-1 clinical trial is funded by Nuvalent.
Dr. Drilon is a paid consultant and member of the scientific advisory board of Nuvalent.
Dr. Drilon’s full disclosures can be found at his physician biography.